Latest Biotechnology, Pharmaceutical and Healthcare News from LaMerie

Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting ...

Biodel Completes Enrollment in Phase 2 Clinical Trial of Ultra-Rapid-Acting Insulin Candidate ...

Top-Line Data Expected in Third Quarter 2013

A total of up to 36 patients were to be studied in the second stage.

Top-Line Data Expected in Third Quarter 2013

Oncolytics Biotech Inc. Meets Primary Overall Statistical Endpoint in U.S. ...

Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. ...

EMA Accepts MAA Submission of Shionogi’s Ospemifene for the Treatment of VVA

Anaeropharma Science Initiates First-in-Human Trial of Novel Recombinant Bifidobacterial ...

Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II ...

Novel sodium channel blocker with excellent pharmacokinetic and safety profile could fill treatment gap for severe pain condition

Pfizer’s BOSULIF (bosutinib) Receives Conditional Marketing Authorization From The European ...

Biogen Idec’s TECFIDERA (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for ...

Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - Reduces Relapses and Disability Progression - Strengthens Biogen Idec’s Portfolio of Innovative Treatments for People Living with MS

Takeda Submits New Drug Applications in Japan for Cell Culture-Based Pandemic Influenza ...

Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson’s ...

Company’s proprietary therapeutic appears to protect key dopamine-producing brain function

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 ...

Study to evaluate NAV4694 in monitoring progression of MCI to Alzheimer’s Disease

CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with ...

Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for ...

Oncodesign signs a partnership agreement and an option for exclusive licensing with Sanofi in ...

Oncodesign will apply its Nanocyclix (R) technology to one of Sanofi's kinase targets

SUCCESSFUL VACCINE DEVELOPMENTS AT THEMIS BIOSCIENCE

Pasteur Institute Technology Proves its Effective Potential

Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass ...

Biotest decides to move into biggest Phase IIb trial in company history

Lundbeck and Otsuka Further Expand Alliance and Enter into Collaboration for the Development ...

Clinical phase II data will be presented at the AAIC in Boston in July A phase III program of more than 2,500 patients will commence during 2013 Lundbeck receives from Otsuka USD 150 million upon signing of the deal Within the two companies' global agreement this is the first of the projects that will ultimately involve co-development and co-promotion of three Lundbeck drug candid...

Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne ...

OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in ...

5 percent of Treated Lesions Demonstrated a Durable Response Of At Least 6 Months

Cangene announces FDA approval of Botulism Antitoxin

Licensure of BAT is Key Milestone in Highly Successful Collaboration with BARDA to Ensure U.S. Preparedness Against Potential Botulism-Related Public Health Risks

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of ...

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for ...

Marketing application for the sodium glucose co-transporter-2 inhibitor follows completion of Phase III registration trials